Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 16 (1) , 47-55
- https://doi.org/10.2165/00063030-200216010-00005
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune GlobulinNew England Journal of Medicine, 2001
- Intravenous immunoglobulins and transforming growth factor βThe Lancet, 1998
- Inhibition of Complement‐Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding PropertiesScandinavian Journal of Immunology, 1995
- Immunologically active proteins in intravenous immunoglobulinThe Lancet, 1993
- Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparationsThe Lancet, 1993
- Manipulating the Immune System with Immune GlobulinNew England Journal of Medicine, 1992
- Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice.Journal of Clinical Investigation, 1986
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986
- Transient Reversal of Thrombocytopenia in Idiopathic Thrombocytopenic Purpura by High-Dose Intravenous Gamma GlobulinNew England Journal of Medicine, 1982
- Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G.Journal of Clinical Investigation, 1980